Saturday, May 2, 2026
Newsletter About
Tech & Science

What’s the deal with Alzheimer’s disease and amyloid?

For decades, scientists have concentrated on what now looks to be a blind alley.

This article was originally published by Ars Technica and is republished here under license.

At the end of last month, a scientific journal pulled a research paper on Alzheimer’s disease.

The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein called amyloid-β was responsible for memory loss in Alzheimer’s disease. On its own, that might not seem notable; bad papers can make it through peer review and are only caught after publication.

But this wasn’t an isolated case. Over the past few years, multiple studies arguing that amyloid-β is the central driver of Alzheimer’s disease have been retracted. Some scientists have even been indicted for fraud over the issue. All the while, none of the drugs targeting this protein and its pathway have had any real clinical effect.

Read full article

Comments

More in Tech & Science

View All →

Leave a Reply

Discover more from The Meridian Review

Subscribe now to keep reading and get access to the full archive.

Continue reading